Current plan
Explorer
Upgrade
limit warning One or more limits reached
Daily profile views
0 / 3
Monthly profile views
0 / 15
Searches (last 30 days)
No linked companies
Get featured as a Team Member in a Finder company.
Team Member at
Add Entity
snc-logo

Startup Nation Finder

My Watchlists
Ecosystem
Startups
Investors
Hubs
Multinationals
Reports toggle reports submenu
BI Dashboards toggle bi dashboards submenu
Saved Searches
Following
Messaging
Notifications
About Us
Glossary
Current plan
Explorer
Pricing plans
warning Payment details required
Daily profile views
0 / 3
Monthly profile views
0 / 15
Searches (last 30 days)

Upgrade your Finder plan

  • Basic CSV download
  • Unlimited profile visits
  • Unlimited searches
  • Ecosystem reports
  • Saved searches, Watchlists & notifications

Create Watchlist

Watchlist name*
Watchlist must have a valid name.
Description (optional)
0/300
Notifications Settings
Public content (accessible by all Finder users)

Add to List

    Notifications settings

    Set Notifications
    Off
    Select notifications to recieve tooltip-info
    Select all

    Email Alerts

    Receive notifications via email

    No Notifications are selected

    Would you like to select any notifications?
    Hey #USER_FULLNAME#!
    Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
    #COMPANY_NAME#’s page on Startup Nation Finder

    The invitation to claim the profile was originally sent to

    or  

    Hey #USER_FULLNAME#!
    Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
    #COMPANY_NAME#’s page on Startup Nation Finder

    Suggest Edits

    Let us know what you think is inaccurate or missing.
    We will check it out and update the profile if needed.

    Claim Profile

    Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

    Create Free Account
    Lock Icon
    Lock Icon
    8 Characters, Uppercase letter (A-Z),
    Lowercase letter (a-z), Digit (0-9)
    Lock Icon
    Passwords do not match
    Already have an account? Sign In
    Or continue with

    Verify your email

    We’ve sent a verification link to email@email.com
    Sign in
    Lock Icon
    Lock Icon
    Reset password
    Don't have an account? Create Account
    Or continue with

    Check your mailbox

    We sent you an email with further instructions to
    email@email.com

    Do not forget to check your spam folder

    Didn’t get the email? Resend email or Contact us

    Password must contain at least 8 characters, one digit, one uppercase and one lowercase letter.

    Save Search

    Dynamic List | Current Companies undefined
    Auto-updated as companies match your search. Ideal for tracking a market of interest
    Search Description
    undefined
    Search must have a valid name.
    Receive notifications via email

    Rename Search

    Search must have a valid name.
    Delete Saved Search Confirmation
    search will be permanently removed from Finder.
    News Analysis
    snackbar-icon
    title
    message
    Home > Multinationals > OPKO Health
    Claimed by owner Last Update Oct 19, 2023 Suggest Edits Claim Profile
    Claimed by owner
    OPKO Health

    OPKO Health

    Pharmaceuticals • United States

    PUBLIC on NASDAQ on Nov, 1995
    PUBLIC on TASE on Aug, 2013
    Terms of Use
    OPKO Health
    About
    Portfolio Exits
    Israeli Portfolio
    News
    Gallery
    Jun 16, 2026
    finance.yahoo.com
    Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
    May 8, 2026
    finance.yahoo.com
    Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
    Mar 27, 2026
    finance.yahoo.com
    Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
    Feb 26, 2026
    finance.yahoo.com
    OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
    Feb 18, 2026
    finance.yahoo.com
    Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
    #Partners
    Feb 8, 2026
    www.globes.co.il
    חברת הטלה-רפואה Hims&Hers הודיעה כי תשווק גרסה משלה לגלולה ווגובי, אך בסופו של דבר ויתרה על המהלך ● בעקבות המלחמה עלה הצורך בטיפול ב"קעקועים טראומטיים" הנגרמים מחדירת רסיסים לעור ● חברת Launch One Acquisition Corp הודיעה כי בסופו של דבר היא לא תמזג לתוכה את חברת מינוביה הישראלית ● חברת ההשקעות ביומד אופקו מרחיבה את שיתוף-הפעולה עם אנטרה ● וכך קופ"ח מכבי מתכוונת להגן על טמפרטורת התרופות ● השבוע בביומד
    #Product Stage #FDA approved/pending approval
    Feb 6, 2026
    finance.yahoo.com
    Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
    #Partners
    Feb 4, 2026
    finance.yahoo.com
    OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
    #Product Stage #Partners #Management Changes
    Nov 14, 2025
    finance.yahoo.com
    Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
    #Product Stage #Partners
    Sep 18, 2025
    finance.yahoo.com
    Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
    #Product Stage #Partners
    Sep 15, 2025
    finance.yahoo.com
    Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
    #Product Stage #Partners
    Jul 31, 2025
    finance.yahoo.com
    OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
    #Product Stage #Partners
    Jul 23, 2025
    finance.yahoo.com
    OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
    #Partners
    Jul 8, 2025
    finance.yahoo.com
    OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
    #Product Stage #Partners
    Jun 29, 2025
    finance.yahoo.com
    OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
    #Product Stage #Partners
    Jun 25, 2025
    finance.yahoo.com
    OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
    #Product Stage #Partners
    Jun 24, 2025
    finance.yahoo.com
    Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
    #Acquisition #Partners
    Sep 12, 2023
    investors.enterabio.com
    Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
    Mar 8, 2020
    en.globes.co.il
    Opko jumps on Covid-19 diagnostic lab announcement
    #Customers #Investment
    Oct 23, 2019
    en.globes.co.il
    Opko Health seeks $100m in NYSE public offering
    #Investment
    Feb 5, 2019
    en.globes.co.il
    Opko to activate shelf prospectus to raise $200m
    #Investment
    Apr 29, 2018
    www.calcalistech.com
    Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
    #Public Trading
    Apr 10, 2018
    www.globes.co.il
    Opko Health to delist from TASE
    #Public Trading
    Apr 16, 2014
    www.globes.co.il
    Opko turns Prolor into Israeli R&D, investment arm
    #Acquisition
    Dec 21, 2011
    www.globes.co.il
    OPKO Health buys FineTech Pharmaceutical for $27.5m
    #Acquisition

    About

    OPKO Health Inc is a multinational corporation that researches, develops, and produces a variety of pharmaceutical technologies. The company pursues diagnostics, genetic testing, cancer treatment, fertility, growth hormone deficiency, and other areas of pharmaceutical research.

    OPKO Israel encompasses two main entities: OPKO Biologics and FineTech Pharmaceutical. OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. They employ advanced technologies such as CTP, reversible PEGylation, and native stabilizer proteins. On the other hand, FineTech is involved in the development of high-value Active Pharmaceutical Ingredients (APIs) and devises methods to bypass patents, facilitating faster commercial progress for its pharmaceutical clients.

    Founded

    In Israel Since

    Employees Worldwide

    Employees In Israel

    Market Cap

    Market Cap Update

    1/2026

    Country

    United States

    News

      (25)
    Jun 16, 2026
    finance.yahoo.com
    Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
    May 8, 2026
    finance.yahoo.com
    Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
    Mar 27, 2026
    finance.yahoo.com
    Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
    Feb 26, 2026
    finance.yahoo.com
    OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
    Feb 18, 2026
    finance.yahoo.com
    Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
    #Partners
    Feb 8, 2026
    www.globes.co.il
    חברת הטלה-רפואה Hims&Hers הודיעה כי תשווק גרסה משלה לגלולה ווגובי, אך בסופו של דבר ויתרה על המהלך ● בעקבות המלחמה עלה הצורך בטיפול ב"קעקועים טראומטיים" הנגרמים מחדירת רסיסים לעור ● חברת Launch One Acquisition Corp הודיעה כי בסופו של דבר היא לא תמזג לתוכה את חברת מינוביה הישראלית ● חברת ההשקעות ביומד אופקו מרחיבה את שיתוף-הפעולה עם אנטרה ● וכך קופ"ח מכבי מתכוונת להגן על טמפרטורת התרופות ● השבוע בביומד
    #Product Stage #FDA approved/pending approval
    Feb 6, 2026
    finance.yahoo.com
    Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
    #Partners
    Feb 4, 2026
    finance.yahoo.com
    OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
    #Product Stage #Partners #Management Changes
    Nov 14, 2025
    finance.yahoo.com
    Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
    #Product Stage #Partners
    Sep 18, 2025
    finance.yahoo.com
    Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
    #Product Stage #Partners
    Sep 15, 2025
    finance.yahoo.com
    Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
    #Product Stage #Partners
    Jul 31, 2025
    finance.yahoo.com
    OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
    #Product Stage #Partners
    Jul 23, 2025
    finance.yahoo.com
    OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
    #Partners
    Jul 8, 2025
    finance.yahoo.com
    OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
    #Product Stage #Partners
    Jun 29, 2025
    finance.yahoo.com
    OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
    #Product Stage #Partners
    Jun 25, 2025
    finance.yahoo.com
    OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
    #Product Stage #Partners
    Jun 24, 2025
    finance.yahoo.com
    Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
    #Acquisition #Partners
    Sep 12, 2023
    investors.enterabio.com
    Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
    Mar 8, 2020
    en.globes.co.il
    Opko jumps on Covid-19 diagnostic lab announcement
    #Customers #Investment
    Oct 23, 2019
    en.globes.co.il
    Opko Health seeks $100m in NYSE public offering
    #Investment
    Feb 5, 2019
    en.globes.co.il
    Opko to activate shelf prospectus to raise $200m
    #Investment
    Apr 29, 2018
    www.calcalistech.com
    Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
    #Public Trading
    Apr 10, 2018
    www.globes.co.il
    Opko Health to delist from TASE
    #Public Trading
    Apr 16, 2014
    www.globes.co.il
    Opko turns Prolor into Israeli R&D, investment arm
    #Acquisition
    Dec 21, 2011
    www.globes.co.il
    OPKO Health buys FineTech Pharmaceutical for $27.5m
    #Acquisition

    The Team

    (1)
    LM
    Laura Moschcovich
    General Manager

    Connect with

    What is the reason for connecting? *
    Please select a reason
    Your company *
    Please fill out this field

    Your organization type *

    Please fill out this field
    Please select a type
    Your position *
    Please fill out this field
    Add invitation message
    0/300

    Sending invitation...

    Locations

    Israel

    Ashlegan 15, Kiryat Gat, Israel

    Offices Abroad

    Miami, FL, USA

    Locations

    Israel

    Ashlegan 15, Kiryat Gat, Israel

    Offices Abroad

    Miami, FL, USA

    Notes

    Content Writer
    undefined
    BI Verification
    undefined
    Phone Number
    undefined
    Israel Register ID
    undefined
    Confidence Score
    undefined
    Missing Fields
    undefined
    Profile Creator
    undefined
    Profile Update
    undefined
    undefined

    Add Article

    0/500